Item 1.01 Entry into a Material Definitive Agreement.

On January 10, 2023, Navidea Biopharmaceuticals, Inc. (the "Company") entered into the First Amendment to Section 382 Rights Agreement ("First Amendment"), which amends the Section 382 Rights Agreement, dated as of April 7, 2022, between the Company and Continental Stock Transfer & Trust Company, LLC, as Rights Agent (the "Original Rights Agreement"). The First Amendment, which was approved by the Company's Board of Directors on January 5, 2023, reduces the "exchange ratio" from five shares of common stock per right to three shares of common stock per right. No other terms of the Original Rights Agreement were amended.

The foregoing summary of the First Amendment is qualified in its entirety by reference to the First Amendment, a copy of which is attached as Exhibit 4.1 and incorporated by reference herein. The Original Rights Agreement is described in and included as Exhibit 4.1 to the Company's Current Report on Form 8-K filed April 12, 2022.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits.

Exhibit

Number Exhibit Description



4.1       First Amendment to Section 382 Rights Agreement dated as of January 10,
        2023 between Navidea Biopharmaceuticals, Inc. and Continental Stock
        Transfer & Trust Company, LLC.

104     Cover Page Interactive Data File (embedded within the Inline XBRL
        document)



                                       2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses